Clinical Trial Update: BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial of BB-10901 in relapsed or refractory solid tumors has completed, evaluating patients with ovarian cancer, Merkel cell carcinoma, and small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma
• Ovarian Cancer
• Small Cell Lung Cancer

Drugs mentioned

• BB-10901

Snippet

Sponsor: ImmunoGen, Inc. | Conditions: Ovarian Cancer, Merkel Cell Carcinoma | Phase 1 | Status: COMPLETED